Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548

by NASDAQ Market News October 7, 2020

NASDAQ Market News
Click here to email author

ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida

Ads